Skip to main content

Table 2 Laboratory parameters measured at onset of CUA and within 6 months before diagnosis (most pejorative value) in CUA and paired dialysis controls

From: Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study

Biological parameter

Recommended rangea

N

Total CUA cases

N

Non dialysis cases

N

Dialysis cases

N

Dialysis controls

P Value

At onset of lesions

 Total serum calcium (mmol/L)

2.10–2.60

89

2.25 (2.12–2.35)

19

2.25 (2.20–2.34)

70

2.23 (2.11–2.38)

138

2.18 (2.08–2.30)

0.04

 Adjusted serum calcium (mmol/L)

2.10–2.60

88

2.50 (2.33–2.60)

18

2.51 (2.43–2.68)

70

2.48 (2.31–2.58)

136

2.26 (2.16–2.40)

< 0.001

 Serum phosphate (mmol/L)

0.8–1.5

89

1.89 (1.50–2.34)

19

1.98 (1.64–2.60)

70

1.87 (1.46–2.29)

138

1.42 (1.13–1.87)

< 0.001

 Calcium phosphate product (mmol2/L2)

 

88

4.35 (3.29–5.23)

18

4.59 (3.70–5.74)

70

4.21 (3.19–5.22)

138

3.18 (2.50–4.01)

< 0.001

 iPTH (pg/mL)

150–600

87

260 (114–605)

17

115 (83–488)

70

336 (141–605)

136

272 (157–466)

0.20

 Normalized iPTH (N)

2–9

87

5.3 (2.1–11.1)

17

2.2 (1.6–10.6)

70

5.3 (2.5–11.1)

136

4.4 (2.4–8.4)

0.04

 iPTH outside of target range between 2 and 9 fold normal range

 

87

51 (58.6%)

17

14 (73.7%)

70

37 (52.9%)

136

58 (42.6%)

0.16

 25-Hydroxyvitamin D (ng/mL)

>  30

68

28.5 (17.9–40.0)

13

24.0 (10.0–34.0)

55

29.9 (18.0–40.0)

101

34.1 (22.0–47.6)

0.18

 Serum Albumin (g/L)

35–45

88

30.9 (28.0–34.0)

18

30.4 (23.9–34.3)

70

31.5 (28.0–34.0)

136

37.0 (33.3–39.2)

< 0.01

 Serum Albumin variation between diagnosis and 6 months before (g/L)

 

80

−2.7 (−5.0; 1.6)

12

−3.8 (−8.5; −0.5)

68

−2.7 (−5.0; 2.0)

134

1.3 (0.0; 4.0)

< 0.001

 CRP (mg/L)

<  5

87

29.0 (8.0–72.0)

17

34.0 (17.5–72.0)

70

23.5 (6.6–64.0)

135

4.2 (1.0–13.8)

< 0.001

 Hemoglobin (g/dL)

10–11.5

89

10.4 (9.7–11.6)

19

10.1 (9.7–11.7)

70

10.6 (9.6–11.5)

136

11.2 (10.1–12.0)

0.007

Worst value within 6 months before onset of CUA

 Total serum calcium (mmol/L)

2.10–2.60

86

2.34 (2.17–2.47)

17

2.33 (2.29–2.38)

69

2.35 (2.17–2.48)

137

2.28 (2.20–2.37)

0.30

 Adjusted serum calcium (mmol/L)

2.10–2.60

81

2.54 (2.37–2.68)

13

2.54 (2.41–2.71)

68

2.54 (2.30–2.67)

135

2.43 (2.31–2.52)

0.05

 Serum phosphorus (mmol/L)

0.8–1.5

86

2.16 (1.75–2.57)

17

2.00 (1.55–2.11)

69

2.25 (1.87–2.70)

137

1.72 (1.44–2.15)

< 0.001

 Calcium phosphate product (mmol2/L2)

 

86

4.81 (4.24–6.02)

17

4.30 (3.57–4.82)

69

5.20 (4.44–6.50)

137

3.94 (3.26–4.88)

< 0.001

 iPTH (pg/mL)

150–600

75

355 (148–710)

10

331 (210–580)

65

435 (148–710)

128

342 (173–526)

0.10

 Normalized iPTH (N)

2–9

75

7.3 (3.3–12.2)

10

6.5 (4.5–12.1)

65

7.3 (3.3–12.2)

128

5.3 (2.8–8.5)

0.02

 iPTH outside of target value between 2 and 9 fold normal range

 

75

56 (62.9%)

10

15 (79.0%)

65

41 (63.1%)

128

59 (46.1%)

0.01

 25-Hydroxyvitamin D (ng/mL)

>  30

59

29.0 (15.0–42.8)

9

13.0 (9.0–25.0)

50

30.0 (18.0–43.0)

101

36.1 (20.4–48.0)

0.32

 Serum Albumin (g/L)

35–45

81

33.0 (29.0–37.0)

13

32.9 (25.0–37.5)

68

33.5 (29.0–37.0)

135

34.0 (32.0–38.0)

0.049

 CRP (mg/L)

<  5

80

39.5 (14.0–79.6)

13

32.0 (5.9–56.0)

67

46.0 (14.1–79.9)

133

13.4 (4.5–40.2)

0.004

  1. Median (IQR) or N (%). P-Value of comparison between dialysis cases and dialysis controls. CRP, C-reactive protein; iPTH, intact parathyroid hormone aAccording to KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 2009; 113: S1–S130. Adjusted serum calcium level was calculated using the following formula: [serum calcium (mmol/L) + 0,025 (40-Albumin)]